4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: August 11, 2023
Period of Report: August 10, 2023
Accession Number: 0001883850-23-000077

View Document ↗ View on SEC.gov ↗